FI973255A0 - Karbatsoliyhdisteiden käyttö verentungosta aiheuttavan sydämen toiminnanvajauksen hoidossa - Google Patents
Karbatsoliyhdisteiden käyttö verentungosta aiheuttavan sydämen toiminnanvajauksen hoidossaInfo
- Publication number
- FI973255A0 FI973255A0 FI973255A FI973255A FI973255A0 FI 973255 A0 FI973255 A0 FI 973255A0 FI 973255 A FI973255 A FI 973255A FI 973255 A FI973255 A FI 973255A FI 973255 A0 FI973255 A0 FI 973255A0
- Authority
- FI
- Finland
- Prior art keywords
- treatment
- congestive heart
- carvedilol
- carbonate sol
- sol compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1995103995 DE19503995C2 (de) | 1995-02-08 | 1995-02-08 | Verwendung von Carvedilol zur Verminderung der Mortalität bei Patienten mit eingeschränkter myocardialer Funktion |
US08/483,635 US5760069A (en) | 1995-02-08 | 1995-06-07 | Method of treatment for decreasing mortality resulting from congestive heart failure |
PCT/EP1996/000498 WO1996024348A2 (en) | 1995-02-08 | 1996-02-07 | Use of carbazole compounds for the treatment of congestive heart failure |
Publications (2)
Publication Number | Publication Date |
---|---|
FI973255A FI973255A (fi) | 1997-08-07 |
FI973255A0 true FI973255A0 (fi) | 1997-08-07 |
Family
ID=26012210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI973255A FI973255A0 (fi) | 1995-02-08 | 1997-08-07 | Karbatsoliyhdisteiden käyttö verentungosta aiheuttavan sydämen toiminnanvajauksen hoidossa |
Country Status (27)
Country | Link |
---|---|
US (6) | US5760069A (zh) |
EP (1) | EP0808162B1 (zh) |
JP (1) | JP3546058B2 (zh) |
KR (1) | KR100295940B1 (zh) |
CN (1) | CN1093760C (zh) |
AT (1) | ATE179891T1 (zh) |
AU (1) | AU702106C (zh) |
BR (1) | BR9607111A (zh) |
CA (1) | CA2212548C (zh) |
CZ (1) | CZ292002B6 (zh) |
DE (1) | DE69602424T2 (zh) |
DK (1) | DK0808162T3 (zh) |
ES (1) | ES2134588T3 (zh) |
FI (1) | FI973255A0 (zh) |
GR (1) | GR3030966T3 (zh) |
HK (1) | HK1014861A1 (zh) |
HU (1) | HUP9900773A3 (zh) |
NO (1) | NO314830B1 (zh) |
NZ (1) | NZ301692A (zh) |
PL (1) | PL321737A1 (zh) |
RO (1) | RO121629B1 (zh) |
RU (1) | RU2197242C2 (zh) |
SI (1) | SI0808162T1 (zh) |
SK (1) | SK106897A3 (zh) |
UA (1) | UA55382C2 (zh) |
WO (1) | WO1996024348A2 (zh) |
ZA (1) | ZA96994B (zh) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5760069A (en) | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
BR9712283A (pt) * | 1996-10-09 | 1999-08-31 | Boehringer Mannheim Pharm Corp | Método para inibir as cinases de proteìnas ativadas por tensão |
ZA989365B (en) * | 1997-10-15 | 1999-04-15 | Boehringer Mannheim Pharm Corp | Preparation for treating alzheimer's disease |
HUP0004345A3 (en) * | 1997-11-12 | 2001-10-29 | Boehringer Mannheim Pharm Corp | Novel oral pharmaceutical compositions containing from carvedilol |
US20020054911A1 (en) * | 2000-05-11 | 2002-05-09 | Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi | Novel oral dosage form for carvedilol |
DE19833119A1 (de) * | 1998-07-23 | 2000-01-27 | Roche Diagnostics Gmbh | Spritzfertige Injektionslösungen enthaltend Carvedilol |
US6664284B2 (en) | 1998-07-23 | 2003-12-16 | Roche Diagnostics Gmbh | Stabilized carvedilol injection solution |
PE20001302A1 (es) * | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
CA2383974A1 (en) * | 1999-09-08 | 2001-03-15 | Nitromed Inc. | Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
US7235237B2 (en) * | 1999-10-29 | 2007-06-26 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
WO2001035961A1 (en) * | 1999-10-29 | 2001-05-25 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
US7708989B2 (en) * | 1999-10-29 | 2010-05-04 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
US7537785B2 (en) * | 1999-10-29 | 2009-05-26 | Nitromed, Inc. | Composition for treating vascular diseases characterized by nitric oxide insufficiency |
US20010036959A1 (en) * | 2000-04-03 | 2001-11-01 | Gabel Rolf Dieter | Carvedilol-hydrophilic solutions |
WO2002000216A1 (en) * | 2000-06-28 | 2002-01-03 | Teva Pharmaceutical Industries Ltd. | Carvedilol |
WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
JP2004525941A (ja) * | 2001-04-02 | 2004-08-26 | スミスクライン・ビーチャム・コーポレイション | 治療方法 |
WO2003028718A1 (en) * | 2001-10-01 | 2003-04-10 | Smithkline Beecham Corporation | Novel formulations of carvedilol |
US20040186158A1 (en) * | 2001-10-02 | 2004-09-23 | Oh Choon K. | Novel composition of carvedilol |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
SE0103749D0 (sv) * | 2001-11-08 | 2001-11-08 | Sahltech Ab | Treatment of congestive heart failure |
WO2003059807A2 (en) * | 2002-01-15 | 2003-07-24 | Teva Pharmaceutical Industries Ltd. | Crystalline solids of carvedilol and processes for their preparation |
AU2003231283A1 (en) * | 2002-04-30 | 2003-11-17 | Sb Pharmco Puerto Rico Inc. | Carvedilol monocitrate monohydrate |
WO2004047724A2 (en) * | 2002-05-16 | 2004-06-10 | Genelabs Technologies, Inc | Aryl and heteroaryl compounds as antibacterial and antifungal agents |
WO2004002472A1 (en) * | 2002-06-27 | 2004-01-08 | Sb Pharmco Puerto Rico Inc. | Carvedilol hydrobromide |
BR0312102A (pt) * | 2002-06-27 | 2007-05-29 | Sb Pharmco Inc | sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento |
SI1362590T1 (en) * | 2002-07-25 | 2004-04-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
US6632832B1 (en) | 2002-09-10 | 2003-10-14 | Dabur Research Foundation | Anti-cancer activity of carvedilol and its isomers |
US20050032879A1 (en) * | 2003-08-07 | 2005-02-10 | Temple Okarter | Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases |
EP1686967A4 (en) * | 2003-11-25 | 2012-08-08 | Smithkline Beecham Cork Ltd | CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES |
JP2007512372A (ja) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール塩、対応する組成物、送達および/または治療方法 |
WO2005051322A2 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts |
US20060014829A1 (en) * | 2004-07-16 | 2006-01-19 | Nitromed, Inc. | Methods for reducing hospitalizations related to heart failure |
EP1781611A1 (en) * | 2005-06-09 | 2007-05-09 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of carvedilol and processes for their preparation |
WO2007097951A2 (en) * | 2006-02-17 | 2007-08-30 | Nitromed, Inc. | Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
WO2007144785A2 (en) * | 2006-03-26 | 2007-12-21 | Uti Limited Partnership | Ryanodine receptor inhibitors and methods relating thereto |
EP2024337A4 (en) * | 2006-05-16 | 2011-09-14 | Nitromed Inc | SOLID DOSAGE FORMULATIONS OF HYDRALAZIN COMPOUNDS |
EP1991527A2 (en) * | 2006-06-28 | 2008-11-19 | Teva Pharmaceutical Industries Ltd | Polymorphous forms of carvedilol phosphate |
EP2114881A1 (en) * | 2007-02-26 | 2009-11-11 | Teva Pharmaceutical Industries Ltd. | Process for the purification of carvedilol or its salts thereof |
US20090076116A1 (en) * | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched carvediolo |
CA2724540C (en) | 2008-05-16 | 2014-07-08 | Corthera, Inc. | Treating dyspnea associated with acute heart failure with relaxin |
WO2011130194A2 (en) | 2010-04-12 | 2011-10-20 | Supernus Pharmaceuticals Inc. | Methods for producing viloxazine salts and novel polymorphs thereof |
MX2014001556A (es) | 2011-08-12 | 2014-03-31 | Boehringer Ingelheim Vetmed | Composicion farmaceutica de sabor enmascarado. |
CA3027368A1 (en) * | 2016-06-13 | 2017-12-21 | Ascendia Pharmaceuticals, Llc | Parenteral sustained-release delivery of carvedilol disperse systems |
US10772869B1 (en) | 2019-07-24 | 2020-09-15 | ECI Pharmaceuticals, LLC | Pharmaceutical compositions including carvedilol and methods of using the same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2815926A1 (de) | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3319027A1 (de) | 1983-05-26 | 1984-11-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten |
SE460945B (sv) * | 1987-01-15 | 1989-12-11 | Lejus Medical Ab | En multipel-unit-dos komposition av furosemid |
US5312828A (en) * | 1989-06-14 | 1994-05-17 | Finkelstein Joseph A | Substituted imidazoles having angiotensin II receptor blocking activity |
US5308862A (en) * | 1993-03-05 | 1994-05-03 | Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 | Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation |
US5760069A (en) | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
-
1995
- 1995-06-07 US US08/483,635 patent/US5760069A/en not_active Ceased
-
1996
- 1996-02-07 BR BR9607111A patent/BR9607111A/pt not_active Application Discontinuation
- 1996-02-07 EP EP96902984A patent/EP0808162B1/en not_active Expired - Lifetime
- 1996-02-07 HU HU9900773A patent/HUP9900773A3/hu unknown
- 1996-02-07 US US10/721,022 patent/USRE40707E1/en not_active Expired - Lifetime
- 1996-02-07 AT AT96902984T patent/ATE179891T1/de not_active IP Right Cessation
- 1996-02-07 ES ES96902984T patent/ES2134588T3/es not_active Expired - Lifetime
- 1996-02-07 JP JP52398296A patent/JP3546058B2/ja not_active Expired - Lifetime
- 1996-02-07 RU RU97114836/14A patent/RU2197242C2/ru not_active IP Right Cessation
- 1996-02-07 AU AU47181/96A patent/AU702106C/en not_active Revoked
- 1996-02-07 CA CA002212548A patent/CA2212548C/en not_active Expired - Fee Related
- 1996-02-07 DK DK96902984T patent/DK0808162T3/da active
- 1996-02-07 CN CN96192902A patent/CN1093760C/zh not_active Expired - Fee Related
- 1996-02-07 WO PCT/EP1996/000498 patent/WO1996024348A2/en not_active Application Discontinuation
- 1996-02-07 CZ CZ19972463A patent/CZ292002B6/cs not_active IP Right Cessation
- 1996-02-07 DE DE69602424T patent/DE69602424T2/de not_active Ceased
- 1996-02-07 RO RO97-01454A patent/RO121629B1/ro unknown
- 1996-02-07 NZ NZ301692A patent/NZ301692A/xx not_active IP Right Cessation
- 1996-02-07 US US08/875,603 patent/US5902821A/en not_active Ceased
- 1996-02-07 SI SI9630081T patent/SI0808162T1/xx not_active IP Right Cessation
- 1996-02-07 PL PL96321737A patent/PL321737A1/xx unknown
- 1996-02-07 KR KR1019970705480A patent/KR100295940B1/ko not_active IP Right Cessation
- 1996-02-07 SK SK1068-97A patent/SK106897A3/sk unknown
- 1996-02-08 ZA ZA9600994A patent/ZA96994B/xx unknown
- 1996-07-02 UA UA97094498A patent/UA55382C2/uk unknown
-
1997
- 1997-08-07 FI FI973255A patent/FI973255A0/fi unknown
- 1997-08-08 NO NO19973667A patent/NO314830B1/no not_active IP Right Cessation
-
1998
- 1998-11-26 HK HK98112352A patent/HK1014861A1/xx not_active IP Right Cessation
-
1999
- 1999-08-11 GR GR990402047T patent/GR3030966T3/el unknown
-
2001
- 2001-05-23 US US09/863,535 patent/US20010044455A1/en not_active Abandoned
-
2002
- 2002-12-19 US US10/324,856 patent/US20030105138A1/en not_active Abandoned
-
2003
- 2003-11-25 US US10/721,020 patent/USRE40000E1/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI973255A0 (fi) | Karbatsoliyhdisteiden käyttö verentungosta aiheuttavan sydämen toiminnanvajauksen hoidossa | |
UA74346C2 (uk) | Похідні амінодикарбонових кислот, їх застосування та лікарський засіб | |
TR200102962T2 (tr) | Yeni tedavi metodu. | |
GEP20053470B (en) | N-Heteroaryl-Pyridinesulfonamide Derivatives and Their Use as Endothelin Antagonists | |
DK0506539T3 (da) | heterocykliske alkylamider, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem | |
FI964332A (fi) | Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen | |
EP0746313A4 (en) | METHOD FOR TREATING SMALL Mouth Ulcers | |
MX9602442A (es) | Un tratamiento con fluoroquinolona a dosis unica elevada. | |
DE69424777D1 (de) | 3,4-diarylchromane zur behandlung von dermatitis | |
SG49692A1 (en) | Process for the production of a pharmaceutical agent for oral or topical administration in the treatment of leishmaniasis | |
HRP950115B1 (en) | The use of carboxylic acid derivatives as medicaments | |
EP1284265A4 (en) | BENZOTHIOPHENE DERIVATIVES AND MEDICINAL USE THEREOF | |
DE69227583D1 (de) | Arylmorpholine, herstellung und verwendung | |
NZ308260A (en) | Use of 5-(substituted biphenyl)-tetrazole derivatives to treat multiple system organ failure | |
ATE167399T1 (de) | Verwendung von sulfasalazin und/oder dessen aktiven metaboliten zur herstellung eines arzneimittels zur behandlung von venöser insuffizienz und venösen ulcera | |
DE68905657D1 (de) | Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen. | |
FR2376661A1 (fr) | Medicaments anthelminthiques renfermant comme substances actives des anilinomethylene-malononitriles | |
AU4361996A (en) | The use of inositoltrisphosphate for the preparing of medicaments | |
ES2118451T3 (es) | Preparado medicamentoso oral que contiene diclofenaco sodico y un acido organico. | |
ATE330597T1 (de) | Verwendung von fibrate zur herstellung eines arzneimittel zur behandlung von kongestiven herzversagens | |
AU4578501A (en) | Method for treating congestive heart failure | |
UA35912A (uk) | Спосіб лікування виразкової хвороби шлунку та дванадцятипалої кишки | |
UA22022A (uk) | Спосіб лікуваhhя хворих з високим ризиком розвитку поліоргаhhої hедостатhості | |
YU15301A (sh) | PRIMENA R (+)- alfa-(2,3-DIMETOKSIFENIL)-1-[2-(4-FLUOROFENIL) ETIL] -4-PIPERIDINMETANOLA ZA LECENJE POREMEĆAJA SPAVANJA | |
SU1352938A1 (ru) | Питательная среда для получения энтеротоксина clostridium perfringens типа а штамма э |